BioCentury
ARTICLE | Product Development

Out with the old

Why Kyprolis and daratumumab could oust Velcade from first-line MM

June 8, 2015 7:00 AM UTC

Data presented at the American Society of Clinical Oncology meeting in Chicago in previously treated multiple myeloma offer the tantalizing prospect that new regimens could move up to supplant Velcade bortezomib as standard of care in first- and second-line patients while extending survival for newly diagnosed patients to more than a decade.

The standouts in MM at ASCO were Kyprolis carfilzomib from Amgen Inc. and daratumumab from Genmab A/S and Johnson & Johnson's Janssen Research & Development LLC unit. Kyprolis bested Velcade on progression-free survival and rates of peripheral neuropathy in patients with relapsed or refractory MM, suggesting the Amgen drug could move up from its current approved use in the third-line setting...